These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 28416487)
1. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Sans M; Gharpure K; Tibshirani R; Zhang J; Liang L; Liu J; Young JH; Dood RL; Sood AK; Eberlin LS Cancer Res; 2017 Jun; 77(11):2903-2913. PubMed ID: 28416487 [TBL] [Abstract][Full Text] [Related]
2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
3. Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors. Moro F; Baima Poma C; Zannoni GF; Vidal Urbinati A; Pasciuto T; Ludovisi M; Moruzzi MC; Carinelli S; Franchi D; Scambia G; Testa AC Ultrasound Obstet Gynecol; 2017 Dec; 50(6):788-799. PubMed ID: 28101917 [TBL] [Abstract][Full Text] [Related]
4. Extrauterine Pelvic Serous Carcinomas: Current Update on Pathology and Cross-sectional Imaging Findings. Katabathina VS; Amanullah FS; Menias CO; Chen MM; Valente PT; Chintapalli KN; Prasad SR Radiographics; 2016; 36(3):918-32. PubMed ID: 27163599 [TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases]. Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635 [TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer. Song IH; Kim KR; Lim S; Kim SH; Sung CO Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157 [TBL] [Abstract][Full Text] [Related]
7. The "Far Left" of the Morphologic Spectrum of Ovarian High-grade Serous Carcinoma: Case Report of a Purely Noninvasive High-grade Serous Carcinoma Mimicking an Ovarian Serous Borderline Tumor. Katsakhyan L; Baraban EG; Dumoff KL; Burger RA; Parikh R; Cooper K Int J Gynecol Pathol; 2021 Mar; 40(2):175-179. PubMed ID: 32168063 [TBL] [Abstract][Full Text] [Related]
8. Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model. Huang D; Gaul DA; Nan H; Kim J; Fernández FM J Proteome Res; 2019 Aug; 18(8):3184-3194. PubMed ID: 31290664 [TBL] [Abstract][Full Text] [Related]
9. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714 [TBL] [Abstract][Full Text] [Related]
10. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma. Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433 [TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma. Ma FH; Qiang JW; Zhang GF; Li HM; Cai SQ; Rao YM J Ovarian Res; 2016 Jul; 9(1):40. PubMed ID: 27377917 [TBL] [Abstract][Full Text] [Related]
12. Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. Ohsuga T; Yamaguchi K; Kido A; Murakami R; Abiko K; Hamanishi J; Kondoh E; Baba T; Konishi I; Matsumura N BMC Cancer; 2017 Aug; 17(1):580. PubMed ID: 28851311 [TBL] [Abstract][Full Text] [Related]
13. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma]. Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294 [No Abstract] [Full Text] [Related]
14. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225 [TBL] [Abstract][Full Text] [Related]
15. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes. Govindarajan M; Ignatchenko V; Ailles L; Kislinger T Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461 [TBL] [Abstract][Full Text] [Related]
16. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma. Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196 [TBL] [Abstract][Full Text] [Related]
17. The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes. Lu L; Wang S; Zhu Q; Qu Y; Gu W; Ning Y; Chen X; Wang Y Pathol Res Pract; 2018 Aug; 214(8):1087-1094. PubMed ID: 29866423 [TBL] [Abstract][Full Text] [Related]
18. HNF-1β in ovarian carcinomas with serous and clear cell change. DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869 [TBL] [Abstract][Full Text] [Related]
19. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer. Klinkebiel D; Zhang W; Akers SN; Odunsi K; Karpf AR Mol Cancer Res; 2016 Sep; 14(9):787-94. PubMed ID: 27259716 [TBL] [Abstract][Full Text] [Related]
20. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study. Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]